# References for High Peak Peptides

> Research bibliography | High Peak Peptides — The High Peak Peptides reading list: childhood growth, GHRH reviews, CJC-1295 pharmacology, ipamorelin animal studies and the published patient trial.

The childhood height trial starts the argument. These are the studies, reviews and editorials that broaden and complicate it.

## Sermorelin clinical sources

The [childhood sermorelin trial](https://pubmed.ncbi.nlm.nih.gov/8772599/) measures a direct growth outcome. The [GHRH review](https://pubmed.ncbi.nlm.nih.gov/39537825/) supplies the broader biological context. Walker’s [case for physiological hormone release](https://pubmed.ncbi.nlm.nih.gov/18046908/) and Blackman’s [caution about aging interventions](https://pubmed.ncbi.nlm.nih.gov/18981489/) are editorials, with arguments to weigh. The [older-adult cognition trial](https://pubmed.ncbi.nlm.nih.gov/22869065/) tested tesamorelin.

## CJC-1295 and ipamorelin

CJC-1295’s record includes albumin chemistry, healthy-adult hormone studies, a mouse growth experiment, serum-protein work and analytical identification of an unknown preparation. The ipamorelin entries cover human pharmacology, the published bowel-surgery trial, rat bone growth and ferret chemotherapy-associated weight loss.

The cardiovascular paper tested a different ghrelin-receptor agonist in rats. I treat that compound distinction as essential when discussing safety. The bibliographic entries below retain each paper’s published identity.

## References

[1] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nature Reviews Endocrinology. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[2] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[3] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Annals of Internal Medicine. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology and Metabolism. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[8] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[9] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[10] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[11] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[12] Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & Behavior. 2024;284:114644. https://pubmed.ncbi.nlm.nih.gov/39043357/
[13] Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. International Journal of Toxicology. 2015;34(2):151-161. https://pubmed.ncbi.nlm.nih.gov/25722321/
[14] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. https://pubmed.ncbi.nlm.nih.gov/25331030/
[15] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/
[16] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. https://pubmed.ncbi.nlm.nih.gov/10373343/

---

An independent field notebook for the GH axis—where every peak keeps its time stamp, every claim keeps its source, and no curve becomes medical advice.